Alzheimer's disease: strategies for disease modification

被引：888

作者：

Citron, Martin ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 05期

关键词：

AMYLOID-BETA-PEPTIDE; POSITRON-EMISSION-TOMOGRAPHY; GAMMA-SECRETASE INHIBITOR; A-BETA; APOLIPOPROTEIN-E; MOUSE MODEL; MEMORY DEFICITS; ANIMAL-MODEL; DOUBLE-BLIND; FOLLOW-UP;

D O I：

10.1038/nrd2896

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Alzheimer's disease is the largest unmet medical need in neurology. Current drugs improve symptoms, but do not have profound disease-modifying effects. However, in recent years, several approaches aimed at inhibiting disease progression have advanced to clinical trials. Among these, strategies targeting the production and clearance of the amyloid-beta peptide - a cardinal feature of Alzheimer's disease that is thought to be important in disease pathogenesis - are the most advanced. Approaches aimed at modulating the abnormal aggregation of tau filaments (another key feature of the disease), and those targeting metabolic dysfunction, are also being evaluated in the clinic. This article discusses recent progress with each of these strategies, with a focus on anti-amyloid strategies, highlighting the lessons learned and the challenges that remain.

引用

页码：387 / 398

页数：12

共 105 条

[31] The neurobiology of zinc in health and disease [J].

Frederickson, CJ ;

Koh, JY ;

Bush, AI .

NATURE REVIEWS NEUROSCIENCE, 2005, 6 (06) :449-462

[32] Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration [J].

Frenkel, D ;

Katz, O ;

Solomon, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (21) :11455-11459

[33] Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals [J].

Galasko, Douglas R. ;

Graff-Radford, Neil ;

May, Susanne ;

Hendrix, Suzanne ;

Cottrell, Barbara A. ;

Sagi, Sarah A. ;

Mather, Gary ;

Laughlin, Mark ;

Zavitz, Kenton H. ;

Swabb, Edward ;

Golde, Todd E. ;

Murphy, Michael P. ;

Koo, Edward H. .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2007, 21 (04) :292-299

[34] Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype? [J].

Gerlai, R .

TRENDS IN NEUROSCIENCES, 1996, 19 (05) :177-181

[35] Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis [J].

Gervais, Francine ;

Paquette, Julie ;

Morissette, Celine ;

Krzywkowski, Pascale ;

Yu, Mathilde ;

Azzi, Mounia ;

Lacombe, Diane ;

Kong, Xianqi ;

Aman, Ahmed ;

Laurin, Julie ;

Szarek, Walter A. ;

Tremblay, Patrick .

NEUROBIOLOGY OF AGING, 2007, 28 (04) :537-547

[36]

Goedert M, 2006, J ALZHEIMERS DIS, V9, P195

[37]

GREEN RC, ALZHEIMERS DEMENT S2, V4, pT165

[38] AMYLOID BETA-PEPTIDE IS PRODUCED BY CULTURED-CELLS DURING NORMAL METABOLISM [J].

HAASS, C ;

SCHLOSSMACHER, MG ;

HUNG, AY ;

VIGOPELFREY, C ;

MELLON, A ;

OSTASZEWSKI, BL ;

LIEBERBURG, I ;

KOO, EH ;

SCHENK, D ;

TEPLOW, DB ;

SELKOE, DJ .

NATURE, 1992, 359 (6393) :322-325

[39] Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics [J].

Hardy, J ;

Selkoe, DJ .

SCIENCE, 2002, 297 (5580) :353-356

[40]

Harrington C, 2009, ALZHEIMERS DEMENT S1, V5, pe17

← 1 2 3 4 5 6 7 8 9 10 →